Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
sotagliflozin
Biotech
EASD: Sanofi, Lexicon eye filing for SGLT1/2 med sotagliflozin
Sanofi and Lexicon aim to carve out a place for their experimental SGLT2/SGLT1 drug sotagliflozin in Type 1 diabetes.
Tracy Staton
Sep 14, 2017 9:54am
Lexicon builds case for Sanofi-partnered diabetes pill
Aug 15, 2017 9:15am
Sanofi-backed Lexicon up after hitting PhIII Type 1 diabetes target
Sep 9, 2016 8:59am
